UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 28, 2008 (July 24, 2008)
BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 0-31361 | 35-2089858 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
801 Corporate Center Drive, Suite #210 Raleigh, NC |
27607 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (919) 582-9050
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 and 8.01. Regulation FD Disclosure and Other Events.
(a) On July 24, 2008, BioDelivery Sciences International, Inc. (the Company) held its 2008 annual meeting of stockholders (the Annual Meeting). At the Annual Meeting, a majority of the Companys shares of common stock represented at the Annual Meeting approved the following proposals:
1. | To elect all five (5) members of the Companys Board of Directors to serve until the 2009, 2010 and 2011 Annual Meetings of Stockholders, as applicable, and until their successors are duly elected and qualified; |
2. | To amend the Companys Certificate of Incorporation to create a classified board of directors comprised of three classes with staggered terms, with the following members of the Companys Board of Directors serving in the following classes: |
Class One (serving for a term of one year, through 2009) : Dr. Frank E. ODonnell, Jr.
Class Two (standing for a term of two years, through 2010) : John J. Shea and Dr. Mark Sirgo
Class Three (standing for a term of three years, through 2011) : William B. Stone and William S. Poole; and
3. | To ratify the appointment by the Audit Committee of the Companys Board of Directors of Cherry, Bekaert & Holland, L.L.P. as the Companys independent auditors for the fiscal year ending December 31, 2008. |
A copy of the Amendment to the Companys Certificate of Incorporate, filed with the Secretary of State of Delaware of July 25, 2008, is attached to this Current Report on Form 8-K as Exhibit 3.1.
(b) On July 28, 2008, the Company issued a press release regarding the initiation of its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral ® Amphotericin B. The press release is attached to this Current Report on Form 8-K as Exhibit
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits |
3.1 |
Amendment to the Companys Certificate of Incorporation, filed July 25, 2008. | |
99.1 |
Press release, dated July 25, 2008, relating to the initiation of a Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral ® Amphotericin B. |
This Current Report on Form 8-K and the exhibits hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements with respect to the Companys plans, objectives, expectations and intentions and other statements identified by words such as may, could, would, should, believes, expects, anticipates, estimates, intends, plans or similar expressions. These statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Companys control).
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
July 28, 2008 |
BIODELIVERY SCIENCES INTERNATIONAL, INC. | |||||
By: |
/s/ James A. McNulty |
|||||
Name: |
James A. McNulty | |||||
Title: |
Secretary, Treasurer and Chief Financial | |||||
Officer |
Exhibit 3.1
CERTIFICATE OF AMENDMENT TO THE
CERTIFICATE OF INCORPORATION OF
BIODELIVERY SCIENCES INTERNATIONAL, INC.
Under Section 242 of the Delaware General Corporation Law
IT IS HEREBY CERTIFIED THAT:
1. The name of the corporation is BioDelivery Sciences International, Inc. (the Corporation). The original Certificate of Incorporation of the Corporation (the Certificate of Incorporation) was filed with the Secretary of the State of Delaware on April 18, 2002.
2. The amendment of the Certificate of Incorporation effected by this Certificate of Amendment is to create a classified board of directors comprised of three classes with staggered terms.
3. The Certificate of Incorporation is hereby amended by added thereto a new Article TWELFTH , and said Article shall read as follows:
TWELFTH: The Board of Directors shall be divided into three classes, each such class as nearly equal in number as the then-authorized number of Directors constituting the Board of Directors permits, with the term of office of one class expiring each year. At the annual meeting of stockholders following approval of amendment to the Certificate of Incorporation, the stockholders shall elect the one class of Directors for a term expiring at the annual meeting of stockholders to be held in 2009, another class of Directors for a term expiring at the annual meeting of stockholders to be held in 2010, and another class of Directors for a term expiring at the annual meeting of stockholders to be held in 2011. Thereafter, each Director shall serve for a term ending at the third annual meeting of stockholders of the Corporation following the annual meeting at which such Director was elected. Members of each class shall hold office until their successors are elected and qualified. At each succeeding annual meeting of the stockholders of the Corporation, the successors of the class of Directors whose term expires at that meeting shall be elected by a plurality vote of all votes cast at such meeting to hold office for a term expiring at the annual meeting of stockholders held in the third year following the year of their election.
4. The amendment of the Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, the Corporation has caused this certificate to be signed by its duly authorized officer signatory below this 24 th day of July, 2008.
BIODELIVERY SCIENCES INTERNATIONAL, INC. | ||
By: |
/s/ James A. McNulty |
|
Name: | James A. McNulty | |
Title: | Chief Financial Officer |
Exhibit 99.1
BioDelivery Sciences Initiates Bioral ® Amphotericin B
Clinical Program
Phase I trial represents the first clinical study in humans utilizing the Companys
Bioral ® drug delivery technology
RALEIGH, N.C., July 28, 2008 BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral ® Amphotericin B. This study represents a significant step forward in the evaluation of BDSIs second drug delivery platform, known as Bioral ® .
The Bioral ® drug delivery system appears to protect certain drugs from degradation in the gastrointestinal tract and facilitates their oral absorption through a novel process of encapsulation. In the Phase I trial, the Bioral ® technology will be evaluated as a potential means of orally delivering the antifungal agent Amphotericin B, an important and well established treatment for serious fungal infections, which is currently administered only by intravenous (IV) injection.
Development of an orally available formulation of Amphotericin B has been a long-term goal of our research laboratory, stated Dr. Raphael Mannino, Executive Vice President and Chief Scientific Officer at BDSI. The ability to orally administer Amphotericin B using the Bioral ® technology could have a major impact on treatment approaches for systemic fungal infections which often require hospitalization and IV therapy. We have conducted several studies in animals showing the efficacy and safety of the technology and have collaborated with other companies in an attempt to provide better stability and oral delivery of their products. This includes programs involving siRNAs, where the greatest challenge is drug delivery. We are also enthusiastic about our collaboration with the National Institutes of Health (NIH), which has supported in part our preclinical program, and more recently our collaboration with the Walter Reed Army Institute of Research exploring the use of the Bioral ® technology in difficult to treat infections.
Dr. Mark Sirgo, President and CEO of BDSI stated, We believe that the initiation of this first clinical study with our Bioral ® delivery technology represents a major milestone for BDSI. We believe that the availability of an oral formulation of Amphotericin B could have very positive public health benefits. Our intention is to evaluate its use for the treatment and prophylaxis of various fungal infections including Candidiasis. This gives BDSI the opportunity to provide the first oral Amphotericin B formulation and enter the over $3 billion global market for systemic antifungal agents. We are hopeful that Bioral ® Amphotericin B will be the first product of several in our pipeline using the Bioral ® drug delivery technology.
The companys lead product, BEMA Fentanyl, is currently under review at the FDA with a PDUFA date of August 31, 2008. BEMA Fentanyl consists of a small, thin, soluble, polymer film, formulated with the opioid fentanyl for application to the buccal (inner lining of cheek) membranes and is being developed to treat breakthrough pain in opioid tolerant patients with cancer.
About the Bioral ® Technology
Bioral ® is a novel drug delivery system, based upon cochleate technology. Bioral ® encapsulates and protects a drug without chemically bonding to it and facilitates oral dosing of drugs that typically need to be given by intravenous administration. Alternating layers of lipids protect or encapsulate a drug molecule by rolling up or spiraling around it. This proprietary structure provides protection from degradation and allows the drug within the structure to remain intact, even though its outer layers may be exposed to harsh conditions, such as the digestive enzymes in the stomach. Use of the Bioral ® technology is being evaluated as a new means of overcoming the poor oral absorption of drugs, such as the antifungal drug Amphotericin B. Several pre-clinical studies have demonstrated the potential value of drugs delivered using the Bioral ® technology. One such study was published in the July 15, 2008, issue of Transplantation , where the Bioral ® technology was shown to be effective for the oral delivery of a potential drug for use in transplantation. 1
1 |
Campo, et al. Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl-s-Triazole Derivative in a Murine Model of Graft-Versus-Host Disease. Transplantation, Vol 86, Number 1, July 15, 2008. |
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is focused on developing innovative products to address growing market opportunities, including conditions such as pain. The company utilizes its owned and licensed patented drug delivery technologies to develop, partner and commercialize new products using proven therapeutics. BDSIs pain franchise currently consists of two products in development utilizing the companys patented BEMA oral adhesive film technology: BEMA Fentanyl, a potential treatment for breakthrough pain in opioid tolerant patients with cancer (NDA currently under review by FDA), and BEMA Buprenorphine, a second analgesic with at least one potential target indication for the treatment of moderate to severe pain. The company is working with its BEMA technology and its patented Bioral ® cochleate technology on products targeted at conditions common to oncology and surgical patients such as pain and infections. The company headquarters is located in Raleigh, North Carolina, and its principal laboratory is located in Newark, New Jersey. For more information please visit www.bdsinternational.com.
Forward-Looking Statements
Note: Except for the historical information contained herein, this press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the Company) related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Companys plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, could, would, should, believes, expects, anticipates, estimates, intends, plans or similar expressions. These statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks and
uncertainties, including those detailed in the Companys filings with the Securities and Exchange Commission. Actual results, including, without limitation: (i) actual sales results and royalty or milestone payments, if any, (ii) the application and availability of corporate funds and the Companys need for future funds, or (iii) the timing for completion, and results of, scheduled or additional clinical trials and the FDAs or other regulatory review and/or approval and commercial launch of the Companys formulations and products and regulatory filings related to the same, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Companys control). Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all.
Contacts:
FD Ashton Partners
Investors: | James Koppa | |
312-553-6709 | ||
james.koppa@fdashtonpartners.com | ||
Media: | Stephanie Brown | |
312-553-6727 | ||
stephanie.brown@fdashtonpartners.com |